Preparation method of absorbable haemostasis material

Abstract

The invention discloses a preparation method of an absorbable haemostasis material. The preparation method comprises the following steps: carrying out a cross-linking reaction on a raw material hyaluronic acid or hyaluronate under the action of low-temperature intermittent ultrasonic treatment, uniformly mixing the crosslinked hyaluronic acid or hyaluronate with low-temperature intermittent ultrasonic treatment unreacted hyaluronic acid or hyaluronate, and carrying out ultralow-temperature freeze drying to obtain the absorbable haemostasis material. The low-temperature ultrasonic dissolving technology greatly shortens the hyaluronic acid dissolving time and reduces the pollution probability of the product in the production process; high-molecular weight hyaluronic acid or hyaluronate which can prolong the in-vivo degradation time through improving the solution concentration to meet the wound healing time has large production cost, and is bad for the reduction of the production cost of enterprises; and medium-and-small-molecular weight hyaluronic acid or hyaluronate undergoes the chemical crosslinking reaction under the low-temperature intermittent ultrasonic conditions, and the crosslinked hyaluronic acid or hyaluronate is mixed with the low-temperature intermittent ultrasonic treatment unreacted hyaluronic acid or hyaluronate according to a certain ratio, so the obtained haemostasis material has the advantages of improvement of the anti-adhesion performance, low residual amount of a crosslinking agent, stabilization of the residual amount in a certain range, reduction of the biological risk brought by free crosslinking agents, and reduction of the production cost of the enterprises.

Description

technical field [0001] The invention belongs to the field of biological materials, and in particular relates to a preparation method of an absorbable hemostatic material. Background technique [0002] Hyaluronic acid is a natural polymeric acidic mucopolysaccharide composed of β-D-glucuronic acid and β-N-acetylglucosamine disaccharide units linked by alternating (1→4) and (1→3) glycosidic bonds , is an important component of human and animal skin, vitreous body, joint lubricant and cartilage tissue, with good physical and chemical properties and biocompatibility. [0003] According to the provisions of the National Pharmacopoeia, the appearance of hyaluronic acid or its salts is white or off-white loose fibrous matter or amorphous powder. In practical applications, hyaluronic acid or its salts are often prepared into aqueous solutions. As a macromolecular substance, it is easy to form a colloid on the surface during the dissolution process, which makes the dissolution proce...

AI Technical Summary

Problems solved by technology

Products that have been marketed abroad, because hyaluronic acid is either unmodified or has a low degree of modification, it is easily degraded by hyaluronidase in the body, and the degradation speed is too fast, which affects its anti-adhesion effect

[0005] Modified hyaluronic acid or its salts will have the problem of cross-linking agent residues. The cross-linking agent has potential carcinogenic toxicity, and the removal of the cross-linking agent will increase with the increase of the amount added. The residual amount of cross-linking agent The problem of poor stability is also recognized in the industry

In order to obtain safe and effective cross-linked hyaluronic acid or its salt products, it is necessary to effectively increase the utilization rate of the cross-linking agent, take effective measures to reduce the residue of the cross-linking agent as much as possible, ensure the stability of the residual amount of the cross-linking agent, and improve the product. Biocompatibility, many problems have not been properly resolved

Images